Waters Co. (NYSE:WAT) Expected to Announce Quarterly Sales of $652.28 Million

Equities research analysts predict that Waters Co. (NYSE:WAT) will announce sales of $652.28 million for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Waters’ earnings. The highest sales estimate is $653.30 million and the lowest is $650.92 million. Waters reported sales of $593.78 million in the same quarter last year, which indicates a positive year-over-year growth rate of 9.9%. The business is scheduled to issue its next quarterly earnings report on Tuesday, October 26th.

According to Zacks, analysts expect that Waters will report full-year sales of $2.76 billion for the current financial year, with estimates ranging from $2.74 billion to $2.78 billion. For the next fiscal year, analysts anticipate that the company will post sales of $2.91 billion, with estimates ranging from $2.88 billion to $2.93 billion. Zacks’ sales averages are an average based on a survey of analysts that cover Waters.

Waters (NYSE:WAT) last released its quarterly earnings results on Tuesday, August 3rd. The medical instruments supplier reported $2.60 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.29 by $0.31. Waters had a return on equity of 387.10% and a net margin of 24.73%. The business had revenue of $681.70 million during the quarter, compared to analysts’ expectations of $625.36 million. During the same quarter in the prior year, the business earned $2.10 earnings per share. The company’s quarterly revenue was up 31.1% compared to the same quarter last year.

A number of research analysts recently weighed in on WAT shares. Zacks Investment Research raised Waters from a “hold” rating to a “buy” rating and set a $418.00 price objective on the stock in a report on Saturday, August 7th. Robert W. Baird upped their price objective on Waters from $297.00 to $360.00 and gave the stock a “neutral” rating in a report on Wednesday, August 4th. SVB Leerink upped their target price on Waters from $370.00 to $385.00 and gave the company a “market perform” rating in a report on Wednesday, August 4th. Citigroup upped their target price on Waters from $315.00 to $400.00 and gave the company a “neutral” rating in a report on Wednesday, August 4th. Finally, Evercore ISI raised Waters from an “in-line” rating to an “outperform” rating and set a $400.00 target price on the stock in a report on Tuesday, July 6th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $306.64.

In other news, Director Linda Baddour sold 1,260 shares of the firm’s stock in a transaction dated Monday, August 16th. The stock was sold at an average price of $408.99, for a total value of $515,327.40. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Michael J. Berendt sold 4,000 shares of the firm’s stock in a transaction dated Thursday, August 12th. The stock was sold at an average price of $398.43, for a total value of $1,593,720.00. Following the completion of the transaction, the director now owns 16,449 shares in the company, valued at $6,553,775.07. The disclosure for this sale can be found here. Insiders have sold 13,260 shares of company stock worth $5,300,907 over the last quarter. 1.10% of the stock is currently owned by company insiders.

Hedge funds have recently bought and sold shares of the company. CWM Advisors LLC grew its stake in shares of Waters by 30.9% in the first quarter. CWM Advisors LLC now owns 5,530 shares of the medical instruments supplier’s stock valued at $1,571,000 after buying an additional 1,307 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Waters by 1.4% in the first quarter. Goldman Sachs Group Inc. now owns 197,192 shares of the medical instruments supplier’s stock valued at $56,036,000 after buying an additional 2,735 shares in the last quarter. Jupiter Asset Management Ltd. grew its stake in shares of Waters by 1.2% in the first quarter. Jupiter Asset Management Ltd. now owns 81,813 shares of the medical instruments supplier’s stock valued at $23,249,000 after buying an additional 959 shares in the last quarter. Logan Capital Management Inc. grew its stake in shares of Waters by 3.0% in the first quarter. Logan Capital Management Inc. now owns 54,605 shares of the medical instruments supplier’s stock valued at $15,517,000 after buying an additional 1,586 shares in the last quarter. Finally, Great West Life Assurance Co. Can grew its stake in shares of Waters by 1.6% in the first quarter. Great West Life Assurance Co. Can now owns 113,279 shares of the medical instruments supplier’s stock valued at $31,975,000 after buying an additional 1,753 shares in the last quarter. Institutional investors and hedge funds own 88.08% of the company’s stock.

WAT stock traded up $6.28 on Tuesday, reaching $409.49. 297,161 shares of the company’s stock were exchanged, compared to its average volume of 370,047. The stock has a fifty day moving average of $395.44 and a 200-day moving average of $338.04. Waters has a twelve month low of $187.31 and a twelve month high of $428.22. The firm has a market cap of $25.13 billion, a PE ratio of 38.70, a P/E/G ratio of 4.20 and a beta of 0.80. The company has a quick ratio of 1.89, a current ratio of 2.41 and a debt-to-equity ratio of 5.98.

Waters Company Profile

Waters Corp. is a specialty measurement company which engages in analytical workflow solutions involving liquid chromatography, mass spectrometry and thermal analysis innovations. It operates through the Waters and TA segments. The Waters segment consists of liquid chromatography instruments, mass spectrometry, and precision chemistry consumable products and related services.

Recommended Story: What is a resistance level?

Get a free copy of the Zacks research report on Waters (WAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Waters (NYSE:WAT)

Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.